pembrolizumab
merck
['breast', 'pembro']
komen scholar dr. pusztai presents that pembrolizumab + chemo increases pcr, decreases residual cancer burden, and results in fewer efs events in the keynote522 trial at #asco22 for early, high risk #triplenegative #breastcancer patients 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ